Anavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Anavex Life Sciences has been given a "Sell (D-)" rating by Weiss Ratings, while other analysts have mixed opinions, with two rating it a Buy and one a Sell.
• The company's share price recently rose to $9.85, with a market cap of approximately $846 million, but it has a 12-month low of $5.03 and a high of $14.44.
• Anavex reported a loss of ($0.16) earnings per share in its last quarterly earnings, which was below analysts' expectations of ($0.13).

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

AVXL has been the subject of several other research reports. HC Wainwright restated a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday. D. Boral Capital restated a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, October 1st. Finally, Wall Street Zen lowered shares of Anavex Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 23rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $44.00.

Anavex Life Sciences Price Performance

Shares of AVXL stock traded up $0.07 on Wednesday, hitting $9.85. The stock had a trading volume of 1,174,573 shares, compared to its average volume of 1,121,772. The business has a 50 day moving average of $9.66 and a 200 day moving average of $9.33. The stock has a market cap of $846.02 million, a price-to-earnings ratio of -17.28 and a beta of 0.83. Anavex Life Sciences has a 12-month low of $5.03 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, research analysts expect that Anavex Life Sciences will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

A number of large investors have recently modified their holdings of the company. PVG Asset Management Corp boosted its position in shares of Anavex Life Sciences by 34.9% in the second quarter. PVG Asset Management Corp now owns 111,445 shares of the biotechnology company's stock valued at $1,028,000 after acquiring an additional 28,837 shares during the period. State of Wyoming bought a new position in shares of Anavex Life Sciences in the second quarter valued at approximately $26,000. Tower Research Capital LLC TRC boosted its position in shares of Anavex Life Sciences by 215.7% in the second quarter. Tower Research Capital LLC TRC now owns 13,850 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 9,463 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Anavex Life Sciences by 1.5% in the second quarter. Ameriprise Financial Inc. now owns 85,990 shares of the biotechnology company's stock valued at $793,000 after acquiring an additional 1,233 shares during the period. Finally, Raymond James Financial Inc. boosted its position in shares of Anavex Life Sciences by 29.2% in the second quarter. Raymond James Financial Inc. now owns 22,130 shares of the biotechnology company's stock valued at $204,000 after acquiring an additional 5,000 shares during the period. 31.55% of the stock is currently owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.